The House Appropriations Committee directed the FDA to reform how it signs off on new clinical trials, pushing for an IND process designed to keep the US pace with global competitors. The move reflects mounting congressional pressure to accelerate trial starts without sacrificing oversight. In parallel, multiple stakeholders urged the FDA to pause its Commissioner’s National Priority Voucher (CNPV) pilot after a listening session. Patient groups and drug makers cited concerns that the “ultra-accelerated” review pathway lacks sufficient transparency and public input, and asked the agency to revert to normal procedures. Separate reporting also highlighted broader compliance pressure as regulatory changes speed up across pricing and program administration, increasing the workload on pharma teams. Together, the actions underscore a regulator that is both faster and more contested—shifting how sponsors plan timelines, documentation, and risk management for development programs.